INNATE PHARMA: New combination trial with lirilumab in hemato-oncology
12 Novembre 2015 - 7:15AM
- 8 trials ongoing with lirilumab in multiple indications and
combinations
- 5 combination trials ongoing in hemato-oncology
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 -
IPH) announced that a new trial performed by the MD Anderson cancer
center started, testing a combination of nivolumab, lirilumab and
5-azacytidine for the treatment of patients with Myelodysplastic
Syndrome (MDS).
This is the third trial with lirilumab supported by
Bristol-Myers Squibb and performed by the MD Anderson cancer center
in 2015, after the opening of one trial testing the combination of
lirilumab and 5-azacytidine in relapsed/ refractory AML and another
trial testing the combination of lirilumab and rituximab in
relapsed/ refractory or high-risk untreated CLL.
These new trials bring to 8 the number of trials performed with
lirilumab, testing a broad range of solid and hematological cancer
indications, multiple rationales and combinations with cytotoxic
antibodies, checkpoint inhibitors and chemotherapy. See
clinicaltrials.gov
About lirilumab (IPH2102/BMS-986015):
Lirilumab is a first-in-class checkpoint inhibitor, fully human
monoclonal antibody (mAb) that blocks the interaction between
Killer-cell immunoglobulin-like receptors (KIR) on NK cells and
their ligands. Blocking these receptors facilitates activation of
NK cells and destruction of tumor cells.
Lirilumab is licensed to Bristol-Myers Squibb Company. As part
of the agreement between Innate Pharma and Bristol-Myers Squibb,
Bristol-Myers Squibb holds exclusive worldwide rights to develop,
manufacture and commercialize lirilumab and related compounds
blocking KIR receptors, for all indications. Under the agreement,
Innate Pharma conducts the development of lirilumab through Phase
II in AML.
Innate is currently testing lirilumab in a randomized,
double-blind, placebo-controlled Phase II trial as maintenance
treatment in elderly patients with Acute Myeloid Leukemia ("AML")
in first complete remission ("EffiKIR" trial). In addition,
lirilumab is also being evaluated by Bristol-Myers Squibb in
clinical trials in combination with other agents in a variety of
tumor types.
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company discovering
and developing first-in-class therapeutic antibodies for the
treatment of cancer and inflammatory diseases.
The Company has three clinical-stage programs, including two
checkpoint inhibitors in immuno-oncology, a new therapeutic field
that is changing cancer treatment by enhancing the capability of
the body's own immune cells to recognize and kill cancer cells.
Its innovative approach has translated into major alliances with
leaders in the biopharmaceutical industry such as Novo Nordisk A/S,
Bristol-Myers Squibb and AstraZeneca.
Listed on Euronext-Paris, Innate Pharma is based in Marseille,
France, and had 112 employees at September 30, 2015.
Learn more about Innate Pharma at www.innate-pharma.com.
Practical Information about Innate Pharma
shares:
ISIN
code Ticker code |
FR0010331421 IPH |
Disclaimer:
This press release contains certain forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. For a
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors ("Facteurs de Risque")
section of the Document de Reference prospectus filed with the AMF,
which is available on the AMF website or on Innate Pharma's
website.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
For additional information, please
contact:
Innate Pharma |
ATCG
Press |
Laure-Hélène Mercier Director,
Investor Relations |
Marie
Puvieux (France) Mob: +33 (0)6 10 54 36 72 Jean-Medhi Grangeon
(ROW) |
Tel.: +33 (0)4 30 30 30 87 |
Mob: +33
(0)6 62 22 00 24 |
investors@innate-pharma.com |
presse@atcg-partners.com |
151112 IPH Update on lirilumab BMS
http://hugin.info/155662/R/1966282/718044.pdf
HUG#1966282
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024